Professor of Neuology/Director, UCLA NeuroOncology Program
Neurology
Dr. Timothy F. Cloughesy, MD
|
|
Give Review
Timothy F. Cloughesy is an expert in the field of Neurology. She graduated from Tulane University School of Medicine. She received awards:"America's Top Doctors", "Top Doctors:LA Area", "America's Top Doctors for Cancer", "Top Doctors:Southern California" and "Super Doctor". Timothy F. Cloughesy is a published doctor as well. She has 101 publications published. The latest was: Reply to comment on: 'Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach'. She accepts all Medicare patients.
Publications
- The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
- Reply to T.J. Kruser et al.
- Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids.
- Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in ne...
- pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI.
- 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.
- MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab.
- Arterial Spin-Labeling Perfusion MRI Stratifies Progression-Free Survival and Correlates with Epidermal Growth Factor Receptor Status in Glioblastoma.
- Relationship Between [(18)F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas.
- Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.
- A novel bicompartmental mathematical model of glioblastoma multiforme.
- Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).
- Tumor suppressive miR-148a is silenced by CpG island hypermethylation in IDH1 mutant gliomas.
- Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group.
- Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.
- Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.
- (18)F-FLT    and (18)F-FDOPA PET kinetics in recurrent brain tumors.
- Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
- C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma.
- Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
- Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
- Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma.
- Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.
- The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings.
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
- Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemoth...
- mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of c-Myc.
- Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicent...
- Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI.
- The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
- Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma.
- Glioblastoma: From Molecular Pathology to Targeted Treatment.
- EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer.
- Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images.
- Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage.
- Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.
- Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
- Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy.
- Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric.
- Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients.
- Evaluation of High Ipsilateral Subventricular Zone Radiation Therapy Dose in Glioblastoma: A Pooled Analysis.
- PDGFRA Amplification is Common in Pediatric and Adult High-Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma.
- Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression.
- Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept.
- Imaging biomarkers for antiangiogenic therapy in malignant gliomas.
- Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma.
- Standards of care for treatment of recurrent glioblastoma--are we there yet?
- Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03.
- Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
- Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
- Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
- Probabilistic radiographic atlas of glioblastoma phenotypes.
- A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
- Glioblastoma therapy in the elderly: one age does not fit all.
- Bevacizumab as first-line therapy for glioblastoma.
- Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-cen...
- 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.
- Regional and Voxel-Wise Comparisons of Blood Flow Measurements Between Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) and Arterial Spin Labeling ...
- Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma.
- Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors.
- Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls.
- Response to C. Massard et al.
- 3'-Deoxy-3'-18F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab.
- Review: Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.
- Oncogenic EGFR signaling activates an mTORC2-NF-?B pathway that promotes chemotherapy resistance.
- Will Kinase Inhibitors Make it as Glioblastoma Drugs?
- Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
- Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells.
- Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblast...
- An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
- Discriminant analysis of ¹â¸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
- Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
- It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology.
- Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab.
- Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab.
- International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study.
- High Order Diffusion Tensor Imaging in Human Glioblastoma.
- Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab.
- A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.
- Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab.
- Clinical trial end points for high-grade glioma: the evolving landscape.
- Considerations for uniform and accurate biospecimen labelling in a biorepository and research environment.
- New strategies in the molecular targeting of glioblastoma: how do you hit a moving target?
- Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
- Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation.
- mTOR signaling in glioblastoma: lessons learned from bench to bedside.
- Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
- The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.
- Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone.
- AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas.
- Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
- Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.
- Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
- Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
- The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.
- Striking the balance between PTEN and PDK1: it all depends on the cell context.
- Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
- Targeted therapy for malignant glioma patients: lessons learned and the road ahead.
- Reply to comment on: 'Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach'.
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:LA Area
- America's Top Doctors for Cancer
- Top Doctors:Southern California
- Super Doctor
Education
-
UCLA Medical Center -
Maricopa Medical Center -
Tulane University School of Medicine
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Drug Facts
| NPI NUMBER | 1154356053 | |
| NPPES Provider LastName | CLOUGHESY | |
| NPPES Provider FirstName | TIMOTHY | |
| NPPES Provider ZIPCode | 900950001 | |
| NPPES Provider State | CA | |
| Specialty Description | Neurology | |
| Total Claim Count | 753.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 19.0 | |
| Percent Opioid Claims | 2.52 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1154356053 |
| Last Name Of The Provider | CLOUGHESY |
| First Name Of The Provider | TIMOTHY |
| View All |
Similar Doctors
|
Dr. Saumya N. Gill, MD |
|
|
Dr. Leon Barton, MD |
|
|
Dr. Nina L. Zasorin, MD |
|
|
Dr. David M. Shaner, MD
 This Doctor is OpenDoctor Recommended.
|